Wednesday, January 11, 2023 8:55:19 AM
Read thru the posts certain experts here maintain the fda is bias towards big pharmaceutical corporations and won’t rush to approve bucc. That’s not my view btw. My view is simple. If the drug works if they plan to manufacture and meet all fda guidelines for the processing and packaging then all good. But what specific does rvvtf have in these areas???
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
